Arbutus Biopharma Corporation ABUS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $169.7M+4,618% | -$3.76M+51.5% | -$7.74M-407% | $2.52M+110% | -$24.53M-95.7% | ||
| $11K0.0% | $11K0.0% | $11K0.0% | $11K-96.7% | $330K-0.9% | ||
| $1.36M+7.7% | $1.26M-0.1% | $1.26M+46.2% | $864K-75.8% | $3.56M+118% | ||
| -$1.16M— | $0+100% | -$120K+23.6% | -$157K+87.2% | -$1.23M-253% | ||
| -$985K— | —— | —— | -$7.6M-267% | $4.55M— | ||
| $195K+115% | -$1.3M-24.8% | -$1.04M-199% | $1.05M+355% | -$413K+64.2% | ||
| -$105K+40.7% | -$177K-14.2% | -$155K-28.1% | -$121K-16.3% | -$104K+16.1% | ||
| $0— | —— | —— | -$9.62M-1,085% | -$812K-70.2% | ||
| $209K+108% | -$2.66M-1,091% | $268K+3.1% | $260K-13.0% | $299K-84.2% | ||
| $178.74M— | —— | —— | —— | $0— | ||
| -$8.11M-73.3% | -$4.68M+19.5% | -$5.82M+63.1% | -$15.75M-17.6% | -$13.39M-29.8% | ||
| $13.8M-46.0% | $25.55M-50.2% | $51.3M+80.0% | $28.5M-17.9% | $34.72M-19.6% | ||
| $16M-32.9% | $23.83M-42.3% | $41.28M-6.4% | $44.1M-4.3% | $46.07M-18.7% | ||
| $2.2M— | —— | —— | $15.61M+37.6% | $11.35M-15.4% | ||
| $11.53M+603% | $1.64M+107% | $794K+75.3% | $453K-82.9% | $2.65M+86.6% | ||
| $11.62M+608% | $1.64M+94.3% | $844K+86.3% | $453K-83.7% | $2.78M+95.9% | ||
| -$10K-1,100% | $1K— | —— | $21K+425% | $4K+112% | ||
| $5.7M+230% | -$4.4M+70.7% | -$15M-4,565% | $336K-55.0% | $746K-83.4% | ||
| $354K-16.1% | $422K-22.0% | $541K-19.0% | $668K-7.0% | $718K-22.2% | ||
| $209K+108% | -$2.66M-1,091% | $268K+3.1% | $260K-13.0% | $299K-84.2% | ||
| $178.74M— | —— | —— | —— | $0— | ||
| $0— | —— | —— | -$9.62M-1,085% | -$812K-70.2% | ||
| $195K+115% | -$1.3M-24.8% | -$1.04M-199% | $1.05M+355% | -$413K+64.2% | ||
| $17K0.0% | $17K-26.1% | $23K-14.8% | $27K-3.6% | $28K-3.4% | ||
| $181K-30.1% | $259K+4.0% | $249K-52.7% | $526K+17.4% | $448K-13.0% | ||
| $0— | —— | —— | —— | $2.81M— | ||
| $16M-32.9% | $23.83M-42.3% | $41.28M-6.4% | $44.1M-4.3% | $46.07M-18.7% | ||
| $88K— | —— | $50K— | —— | $131K— | ||
| —— | -$4.68M+19.5% | -$5.82M+63.1% | -$15.75M-17.6% | -$13.39M-28.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Arbutus Biopharma Corporation generate?
- Arbutus Biopharma Corporation (ABUS) generated -$34.4M in operating cash flow over the trailing twelve months.
- Where does Arbutus Biopharma Corporation's cash flow data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
